JP Morgan Chase’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4,945
| Closed | -$14.1K | – | 7476 |
|
|
2025
Q3 | $14.1K | Buy |
4,945
+3,168
| +178% | +$8.21K | ﹤0.01% | 6564 |
|
|
2025
Q2 | $2.68K | Buy |
1,777
+80
| +5% | +$116 | ﹤0.01% | 6497 |
|
|
2025
Q1 | $2.1K | Sell |
1,697
-3,876
| -70% | -$5.74K | ﹤0.01% | 6540 |
|
|
2024
Q4 | $10K | Buy |
5,573
+5,490
| +6,614% | +$10.2K | ﹤0.01% | 6391 |
|
|
2024
Q3 | $178 | Hold |
83
| – | – | ﹤0.01% | 6918 |
|
|
2024
Q2 | $155 | Hold |
83
| – | – | ﹤0.01% | 6822 |
|
|
2024
Q1 | $220 | Hold |
83
| – | – | ﹤0.01% | 6798 |
|
|
2023
Q4 | $256 | Sell |
83
-4,940
| -98% | -$11.7K | ﹤0.01% | 7024 |
|
|
2023
Q3 | $7.94K | Buy |
5,023
+4,504
| +868% | +$8.8K | ﹤0.01% | 6301 |
|
|
2023
Q2 | $1.02K | Sell |
519
-822
| -61% | -$1.58K | ﹤0.01% | 6450 |
|
|
2023
Q1 | $3K | Sell |
1,341
-257
| -16% | -$644 | ﹤0.01% | 6337 |
|
|
2022
Q4 | $3K | Buy |
1,598
+248
| +18% | +$562 | ﹤0.01% | 6239 |
|
|
2022
Q3 | $3K | Buy |
1,350
+407
| +43% | +$1.23K | ﹤0.01% | 6183 |
|
|
2022
Q2 | $3K | Sell |
943
-1,466
| -61% | -$5.16K | ﹤0.01% | 6238 |
|
|
2022
Q1 | $11K | Buy |
2,409
+604
| +33% | +$3.33K | ﹤0.01% | 6185 |
|
|
2021
Q4 | $15K | Buy |
1,805
+458
| +34% | +$4.5K | ﹤0.01% | 6266 |
|
|
2021
Q3 | $17K | Buy |
1,347
+413
| +44% | +$5.72K | ﹤0.01% | 6080 |
|
|
2021
Q2 | $14K | Buy |
934
+910
| +3,792% | +$15.3K | ﹤0.01% | 5983 |
|
|
2021
Q1 | $0 | Hold |
24
| – | – | ﹤0.01% | 6089 |
|
|
2020
Q4 | $1K | Buy |
24
+12
| +100% | +$269 | ﹤0.01% | 5542 |
|
|
2020
Q3 | $0 | Sell |
12
-25,218
| -100% | -$447K | ﹤0.01% | 5503 |
|
|
2020
Q2 | $449K | Sell |
25,230
-8,711
| -26% | -$133K | ﹤0.01% | 3899 |
|
|
2020
Q1 | $312K | Buy |
+33,941
| New | +$506K | ﹤0.01% | 4072 |
|
|
2019
Q4 | – | Sell |
-14,705
| Closed | -$153K | – | 5624 |
|
|
2019
Q3 | $153K | Buy |
14,705
+9,357
| +175% | +$126K | ﹤0.01% | 4739 |
|
|
2019
Q2 | $82K | Sell |
5,348
-61,953
| -92% | -$1.11M | ﹤0.01% | 5001 |
|
|
2019
Q1 | $1.24M | Buy |
67,301
+12,824
| +24% | +$227K | ﹤0.01% | 3677 |
|
|
2018
Q4 | $907K | Buy |
54,477
+5,960
| +12% | +$138K | ﹤0.01% | 3801 |
|
|
2018
Q3 | $1.37M | Buy |
48,517
+48,317
| +24,159% | +$1.39M | ﹤0.01% | 3713 |
|
|
2018
Q2 | $6K | Sell |
200
-64,945
| -100% | -$1.93M | ﹤0.01% | 5417 |
|
|
2018
Q1 | $2.05M | Buy |
65,145
+35,580
| +120% | +$1.12M | ﹤0.01% | 3251 |
|
|
2017
Q4 | $862K | Buy |
29,565
+10,755
| +57% | +$293K | ﹤0.01% | 3802 |
|
|
2017
Q3 | $517K | Buy |
+18,810
| New | +$486K | ﹤0.01% | 3817 |
|
|
2017
Q1 | – | Sell |
-4,913
| Closed | -$83K | – | 5059 |
|
|
2016
Q4 | $83K | Buy |
+4,913
| New | +$90.8K | ﹤0.01% | 4442 |
|
|
2016
Q1 | – | Sell |
-300,000
| Closed | -$9.31M | – | 4680 |
|
|
2015
Q4 | $9.31M | Hold |
300,000
| – | – | ﹤0.01% | 1865 |
|
|
2015
Q3 | $7.91M | Hold |
300,000
| – | – | ﹤0.01% | 1932 |
|
|
2015
Q2 | $10.8M | Sell |
300,000
-746
| -0.2% | -$26.2K | ﹤0.01% | 1876 |
|
|
2015
Q1 | $10.4M | Buy |
+300,746
| New | +$10.9M | ﹤0.01% | 1881 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
JP Morgan Chase's CLLS Position: Q4 2025 in Review
JP Morgan Chase sold out of Cellectis (CLLS) in Q4 2025, closing a stake of 4,945 shares — an estimated $14.1K sold.
JP Morgan Chase first reported a position in CLLS in Q1 2015 and held it in 37 quarters. The position peaked at $10.8M in Q2 2015. 34 funds tracked by Wall St. Rank hold CLLS as of Q4 2025.
- JP Morgan Chase reported no remaining Cellectis position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 4,945 Cellectis shares in Q4 2025, an estimated $14.1K.
- JP Morgan Chase first reported a position in Cellectis in Q1 2015 and held it in 37 quarters.
- JP Morgan Chase's Cellectis position peaked at $10.8M in Q2 2015.
- 34 funds tracked by Wall St. Rank held Cellectis as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.